Classic Hodgkin lymphoma

This study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…

This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patien…

This study tests a combination of two drugs, camrelizumab and ivarmacitinib, as a first treatment for children aged 6-18 with newly diagnosed classical Hodgkin lymphoma. The goal is to see if this approach can achieve a complete metabolic response (no signs of active cancer) whil…

This early-stage trial tests a new treatment for children, adolescents, and young adults with a certain type of Hodgkin lymphoma that has come back after initial therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer…

This trial tests whether giving CD30-targeting CAR T-cells after a strong chemotherapy and stem cell transplant is safe and feasible for children, teens, and young adults with poor-risk classical Hodgkin lymphoma. About 21 participants aged 6 to 29 will receive the treatment. The…

This study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…